Intervention

ART

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 11 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials11

Recruiting1

Common conditions9

Lead sponsors shown7

Clinical trials

11 shown

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV RemissionNCT05719441 · 2024-08-19

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected AdultsNCT05890963 · 2023-11-28

ACTIVE_NOT_RECRUITING

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)NCT05631093 · 2023-02-20

ACTIVE_NOT_RECRUITING

A Safety Study of Brentuximab Vedotin in Participants With HIVNCT05244473 · 2022-12-31

Effects of COVID-19 on Endothelium in HIV-Positive Patients in Sub-Saharan AfricaNCT04709302 · 2021-02-01

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)NCT04223778 · 2020-02-18

Dual bNAb Treatment in ChildrenNCT03707977 · 2019-06-17

Partners PrEP ProgramNCT03586128 · 2018-06-08

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected ControllersNCT03060447 · 2017-05-09

Partners Demonstration Project of PrEP and ARTNCT02775929 · 2012-11-01

Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3NCT00000948 · 1998-02-01

Common conditions

HIV Infection3 HIV Infections2 HIV-1 Infection2 Acute HIV Infection1 ART1 Covid191 Hiv1 HIV-1-infection1 Human Immunodeficiency Virus1

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID) 3 Merck Sharp & Dohme LLC 2 University of Washington 2 David Ho 1 Gilead Sciences 1 Medical University of Graz 1 Seagen Inc. 1

Trial status mix

COMPLETED6

ACTIVE_NOT_RECRUITING2

RECRUITING1

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE14

PHASE23

PHASE32

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.